Curis
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
128 Spring St Ste 500 Bldg C, Lexington,...Phone Number
(617) 503-6500Website
www.curis.comRevenue
$7.1 MillionStock Symbol
CRISIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Curis
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis. TheRead more
Curis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Curis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if Curis had a recent Job posting/layoffs
Curis, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Curis launches new products
Earning: See what the market has to say on Curis recently announced quarterly report
Check if Curis has recently received funding, and reach out quickly before it becomes old news!
Check out if Curis is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Curis
Funding: Get notified immidiatlly once Curis has new funding data
Recommended Actions
Reach out to Masked Content who joined Curis as Masked Content
Find 3 more new buyers
Compare Similar Companies to Curis
Compare insights from companies similar to Curis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Curis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Curis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Curis.
Curis financials insights
Gather financial insights about Curis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Corporate Investment
$8M
2012
Debt
$30M
2015
Stock Offering
$64.7M
2020
Share Placement
$30M
Debt
$350K
2026
Private Equity
$20.2M
Curis Tech Stack
A closer look at the technologies used by Curis
Most Recent Scoops
Person-Based
Compliance, Stake & Stock Ownership, Finance
Person-Based
Clinical Operations
Person-Based
Medical Research, Clinical Operations
Person-Based
Clinical Operations
Person-Based
Medical Research
Curis News & Media
Curis Announces Positive Emavusertib Update
Updated Clinical Data in PCNSL Increased Guidance on Year-End Data in CLL Company to Host Webcast at 8:30 a.m. ET LEXINGTON, Mass., July 22, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available,...Curis Consents First Six Patients in TakeAim CLL Study
LEXINGTON, Mass., July 6, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment milestone in its TakeAim CLL study....Curis opens 11 sites for emavusertib combo in TakeAim CLL trial
Curis plans to dose the initial five patients by the end of July 2026, with data anticipated in December 2026.Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
Eleven sites open for patient enrollment in TakeAim CLL combination study with zanubrutinib; Company reaffirms guidance for dosing of initial five patients by end of July 2026 with data expected December 2026; Stockholders approve reverse stock split LEXINGTON, Mass., June 26, 2026...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Curis
Sign Up For FreeTo access detailed company insights
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory d... Read More
